- Details
- Cora Sternberg joins Alicia Morgans at ASCO GU 2020 and discusses the significant advancements in the treatment of advanced bladder cancer looking back over the last 30 years. MVAC was regulatory approved as the first line treatment in metastatic bladder cancer thirty years ago. Cora discusses the recent progress that is offering significant improvements in the overall survival for those patients...
|
- Details
- Phillip Koo interviews Jeremie Calais about PSMA PET imaging in patients with localized prostate cancer. Professor Calais discusses the advantages of whole-body PSMA PET imaging in patients with presumed localized cancer, as well as those likely to have extraprostatic disease. The PSMA whole-body imaging modality can be used to identify cancer lesions with high sensitivity in patients. PSMA PET is...
|
- Details
- Matt Cooperberg hosts a discussion with Peter Carroll and Laurence Klotz examining their roles in the progress of active surveillance for low-risk prostate cancer and how they incorporate this treatment into clinical practice. They discuss the change in the field from over-detection and overtreatment where radiation and surgery were the primary treatment options to the evolution of active surveill...
|
- Details
- Ana Aparicio joins Alicia Morgans at ASCO GU 2020 to discuss her work with AR indifferent tumors in the field of prostate cancer. Among the topics discussed, Dr. Aparicio stressed the importance of understanding clinical features and the development of a profile of this AR indifferent subtype in order to allow for easier identification. The two further discuss the research and ongoing clinical tri...
|
- Details
- Hannah Rush joins Alicia Morgans discussing the quality of life outcomes we have seen from patients receiving docetaxel or abiraterone in the STAMPEDE trial. STAMPEDE is a multi-arm, multi-stage trial investigating various therapeutic strategies for the management of locally advanced or metastatic hormone-naïve prostate cancer. In recent years, both docetaxel and abiraterone have been shown to imp...
|
- Details
- Joining Alicia Morgans is Matt Galsky to discuss the biggest updates in bladder cancer clinical trials. Building off of his overview of IMvigor130, KEYNOTE-361, and JAVELIN Bladder 100, Dr. Galsky provides insight on how he incorporates clinical data into his everyday practice and the direction he believes the field is moving towards in the future. Biographies: Matthew Galsky, MD Director of Genit...
|
- Details
- Sam Chang joins Ashish Kamat to discuss strategies for clinical trials and patient selection required in the face of the world-wide shortage of BCG. Biographies: Sam S. Chang, MD, MBA , Patricia and Rodes Hart Endowed Chair of Urologic Surgery Professor Department of Urology at Vanderbilt University Medical Center, Department of Urology Ashish Kamat, MD, MBBS Professor of Urology and Wayne B. Dudd...
|
- Details
- Joshua Meeks joins Ashish Kamat in discussing the most recent relevant research papers in bladder cancer. Together they explore the publications on checkpoint inhibitors, the use of The Cancer Genome Atlas, Enhanced Recovery after Cystectomy and the impact of blue light flexible cystoscopy with CYSVIEW. Biographies: Josh J. Meeks, MD, Ph.D., Assistant Professor of Urology and Biochemistry and Mole...
|
- Details
- Ashish Kamat welcomes a fellow bladder cancer colleague, John Taylor, to discuss international research partnerships among clinicians and organizations. Taylor and Kamat both were essential in the founding of the Leo & Anne Albert Institute of Bladder Cancer Cancer and Research, which provides a platform for clinicians to collaborate on the most recent bladder cancer research. Dr. Taylor also shar...
|
- Details
- Matt Galsky joins Ashish Kamat at ASCO GU 2020 to discuss the most recent advancements in the field of adjuvant therapy in bladder cancer. Together they discuss immune checkpoint blockade therapy in bladder cancer, how to factor in prior therapy for patients considering adjuvant therapy, and Dr. Galsky’s personal research on pathologic complete response. Biography: Matthew Galsky, MD Director of G...
|
